Clinical Trials Logo

Fatty Liver clinical trials

View clinical trials related to Fatty Liver.

Filter by:

NCT ID: NCT06325254 Recruiting - Clinical trials for Metabolic Associated Fatty Liver Disease

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

Start date: January 1, 2010
Phase:
Study type: Observational

Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. With the improvement of living standards and changes in dietary habits, MAFLD patients show a younger and increasing trend, but there is still no specific drug. The clinical features and prognosis of MAFLD may be different with different metabolic disorder phenotypes and treatment measures. Therefore, further systematic study of the clinical characteristics and prognosis of MAFLD patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.

NCT ID: NCT06321211 Not yet recruiting - Clinical trials for Fatty Liver, Nonalcoholic

Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD

aMed
Start date: April 15, 2024
Phase:
Study type: Observational

The goal of this pre-intervention study is test the acceptability of Asian version of the Mediterranean diet to NAFLD patients. The main question[s] it aims to answer are: 1. Whether Asian version of the Mediterranean diet that retains the nutritional composition and can be developed by mapping the components of the Mediterranean diet and finding substitute ingredients commonly eaten in Southeast Asia. 2. Whether the 4-week menu cycle of newly developed novel Asian Mediterranean diet is acceptable among Singaporean local population. Participants will participate in taste test sessions to find out if the Asian Mediterranean diet meals are acceptable to people with NAFLD.

NCT ID: NCT06318169 Recruiting - Clinical trials for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).

NCT ID: NCT06309992 Not yet recruiting - Obesity Clinical Trials

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight

Start date: March 20, 2024
Phase: Phase 3
Study type: Interventional

This study is open to adults who are at least 18 years old and have - presumed or confirmed NASH together with overweight or obesity and - a body mass index (BMI) of 30 kg/m² or more, or - a BMI of 27 kg/m² and at least one weight-related health problem. People with a history of other chronic liver diseases cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people living with obesity or overweight and a confirmed or presumed liver disease called nonalcoholic steatohepatitis (NASH) to have less liver fat and to lose weight. Participants are put into 2 groups randomly, which means by chance. 1 group gets different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week for about 1 year. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 3 months. During this time, it is planned that participants visit the study site up to 13 times and receive 3 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At 3 of the visits, the participants' liver is measured using different imaging methods. The results are compared between the groups to see whether the treatment works.

NCT ID: NCT06308874 Completed - Clinical trials for Non-alcoholic Steatohepatitis

Phase 1 Study to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

Start date: January 2, 2023
Phase: Phase 1
Study type: Interventional

- Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.

NCT ID: NCT06308861 Completed - Clinical trials for Non-alcoholic Steatohepatitis

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Start date: August 12, 2020
Phase: Phase 1
Study type: Interventional

1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2. Design: A dose block-randomized, double-blind, placebo controlled, single- and multiple dosing, dose-escalation phase 1 clinical trial

NCT ID: NCT06308757 Recruiting - Obesity Clinical Trials

Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis

KETONASH
Start date: September 29, 2021
Phase: N/A
Study type: Interventional

The purpose of the KETONASH study is to evaluate, in patients with metabolic-associated fatty liver disease (MAFLD) with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis, the effect of a very low-calorie ketogenic diet (VLCKD) compared to that of a standard low-calorie diet (standard Mediterranean LCD - in accordance with the European Association for the Study of the Liver/European Society for Clinical Nutrition and Metabolism guidelines on MAFLD/NAFLD).

NCT ID: NCT06302049 Not yet recruiting - Fatty Liver Disease Clinical Trials

Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis

Start date: May 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to test the implication of esomeprazole as a possible potential therapy for patients with NASH through evaluating its effect on ultrasound and fibrosis risk scores, serum levels of liver fibrosis biomarkers (fibronectin 1), insulin resistance, metabolic and inflammatory parameters.

NCT ID: NCT06298318 Enrolling by invitation - Hepatic Steatosis Clinical Trials

Metabolic Changes in Healthy Subjects With Acute Binge Drink

MeABD
Start date: March 18, 2024
Phase: N/A
Study type: Interventional

The goal of this double-blinded, randomized trial is to investigate the effects of acute binge drink on liver function, liver fat content and lipid metabolism in healthy young subjects. The main questions it aims to answer are: 1. if acute binge drink could alleviate liver injury and hepatic steatosis.

NCT ID: NCT06297434 Recruiting - Clinical trials for Non-alcoholic Steatohepatitis

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.